Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q1 2024 Earnings Presentation
10 slides from Phibro Animal Health's earnings presentation, Nov 9, 2023
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call November 9, 2023 Financial Results U.S. toll-free +1.888.330.2022 Fiscal Year 2024 International toll +1.365.977.0051 First Quarter Ended September 30, 2023 Conference ID: [3927884] 1 November 9, 2023 Webcast & Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statements other than statements of historical or current
Slide 3: Key Themes
Key Themes Three months ending September 30, 2023 Continuing to invest in Growth in our Animal Updated guidance for Vaccines and Nutritional Health business fiscal year 2024 Specialties Animal Health sales and Phibro remains committed to We updated fiscal year 2024 adjusted EBITDA growth of 4% its g
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated First Quarter, Year-on-Year comparison $ in millions, except per share data ▪ Net Sales – decreased $1.2 million, or 1%. Animal Health grew 4%, YOY offset by declines in Mineral Nutrition and Performance Products Q1 %∆ ▪ Net Income & Diluted EPS – decreased $11.9
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health First Quarter, Year-on-Year comparison $ in millions YOY Net Sales – increased $5.7 million, or 4% ▪ Vaccines Q1 %∆ ▪ Increased $3.2 million, or 14%, due to Animal Health poultry product introduction in Latin America and growth in the U.S. swine sector, partiall
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments First Quarter, Year-on-Year comparison $ in millions ▪ Mineral Nutrition YOY - Net sales decreased $3.6 million, or 6%, due to declines in the Q1 %∆ average selling prices and reduced volumes due to reduced Mineral Nutrition demand Net Sales $ 56.0 (6%) - Adjus
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics September 30, 2023 $4 million of TTM free cash flow; TTM operating cash Free Cash Flow (1) flow of $40 million less capital expenditures of $36 million 4.4x gross leverage ratio; $484 million total debt / $109 Leverage million TTM adjusted EBITDA Quarterly dividend of $0.1
Slide 8: Financial Guidance
Financial Guidance Fiscal Year 2024 $ in millions, except earnings per share (EPS) data FY 2023 FY 2024 FY 2024 • The updated guidance reflects reduced expectations for the fiscal year, compared with Previous Updated our previous guidance; Actual Low High Low High Consolidated ￚ reflecting difficult
Slide 9: Q&A
Q&A 9 November 9, 2023 Webcast & Conference Call
Slide 10: © 2022 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy
© 2022 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy Animals. Healthy Food. Healthy World.; and any other Phibro brand or brands shown herein are trademarks owned by or licensed to Phibro Animal Health Corporation or its affiliates. Any other trademark that